BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1265 related articles for article (PubMed ID: 28652049)

  • 21. The clinical application of 320-detector row CT in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma.
    Du F; Jiang R; Gu M; He C; Guan J
    Radiol Med; 2015 Aug; 120(8):690-4. PubMed ID: 25698303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
    Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences Between CT-Perfusion and Biphasic Contrast-enhanced CT for Detection and Characterization of Hepatocellular Carcinoma: Potential Explanations for Discrepant Cases.
    Perl RM; Portugall J; Hinterleitner C; Hinterleitner M; Kloth C; Walter SS; Bitzer M; Horger MS
    Anticancer Res; 2021 Mar; 41(3):1451-1458. PubMed ID: 33788737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model.
    Choi SH; Chung JW; Kim HC; Baek JH; Park CM; Jun S; Kim MU; Lee ES; Cho HR; Jae HJ; Lee W; Park JH
    Invest Radiol; 2010 Jul; 45(7):427-36. PubMed ID: 20440211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography.
    Moschouris H; Malagari K; Dimakis A; Kiakidis T; Anagnostopoulou A
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1075-1083. PubMed ID: 32394087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
    Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
    J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
    Mulé S; Thiefin G; Costentin C; Durot C; Rahmouni A; Luciani A; Hoeffel C
    Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of the portal venous phase in evaluation of treated hepatocellular carcinoma following transcatheter arterial chemoembolisation.
    Lam A; Fernando D; Sirlin CC; Nayyar M; Goodwin SC; Imagawa DK; Lall C
    Clin Radiol; 2017 Nov; 72(11):994.e9-994.e16. PubMed ID: 28779950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of texture analysis based on enhanced MRI for predicting an early therapeutic response to transcatheter arterial chemoembolisation combined with high-intensity focused ultrasound treatment in hepatocellular carcinoma.
    Yu JY; Zhang HP; Tang ZY; Zhou J; He XJ; Liu YY; Liu XJ; Guo DJ
    Clin Radiol; 2018 Aug; 73(8):758.e9-758.e18. PubMed ID: 29804627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Ippolito D; Querques G; Pecorelli A; Talei Franzesi C; Okolicsanyi S; Strazzabosco M; Sironi S
    J Comput Assist Tomogr; 2019; 43(2):206-213. PubMed ID: 30407241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment.
    Reiner CS; Gordic S; Puippe G; Morsbach F; Wurnig M; Schaefer N; Veit-Haibach P; Pfammatter T; Alkadhi H
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):400-8. PubMed ID: 26216725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.
    Bargellini I; Bozzi E; Campani D; Carrai P; De Simone P; Pollina L; Cioni R; Filipponi F; Bartolozzi C
    Eur J Radiol; 2013 May; 82(5):e212-8. PubMed ID: 23332890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization.
    Yang L; Zhang XM; Zhou XP; Tang W; Guan YS; Zhai ZH; Dong GL
    J Vasc Interv Radiol; 2010 Dec; 21(12):1841-6. PubMed ID: 20980165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
    Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
    Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images.
    Kim HC; Kim AY; Han JK; Chung JW; Lee JY; Park JH; Choi BI
    Radiology; 2002 Dec; 225(3):773-80. PubMed ID: 12461260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC.
    Zhou W; Lv Y; Hu X; Luo Y; Li J; Zhu H; Hai Y
    Front Oncol; 2022; 12():957737. PubMed ID: 36387217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE.
    Nörthen A; Asendorf T; Shin HO; Hinrichs JB; Werncke T; Vogel A; Kirstein MM; Wacker FK; Rodt T
    Abdom Radiol (NY); 2018 Dec; 43(12):3288-3300. PubMed ID: 29680967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applying arterial enhancement fraction (AEF) texture features to predict the tumor response in hepatocellular carcinoma (HCC) treated with Transarterial chemoembolization (TACE).
    Mao X; Guo Y; Wen F; Liang H; Sun W; Lu Z
    Cancer Imaging; 2021 Aug; 21(1):49. PubMed ID: 34384496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization.
    Moschouris H; Malagari K; Papadaki MG; Kornezos I; Stamatiou K; Anagnostopoulos A; Chatzimichael K; Kelekis N
    Diagn Interv Radiol; 2014; 20(2):136-42. PubMed ID: 24317334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.